BlueJet Healthcare Q1 Results FY27: PAT at Rs 78 Cr for June 2026 Quarter

BlueJet Healthcare Q1 FY27: PAT Rs 78 Cr (-14.20% YoY) | Revenue Rs 293 Cr (-17.40% YoY) | EBITDA margin 33.4%. Reported 12:54 PM IST, 3 August 2026.

The BlueJet Healthcare Q1 results FY27 show revenue of Rs 293 Cr for the quarter ended 30 June 2026, -17.40% year on year from Rs 355 Cr in Q1 FY26, as BlueJet Healthcare reported its June quarter numbers at 12:54 PM IST on 3 August 2026. BlueJet Healthcare posted net profit of Rs 78 Cr for the quarter, against Rs 91 Cr in Q1 FY26, a change of -14.20%.

India’s healthcare sector is in a structural multi-year upcycle, driven by rising insurance penetration, government schemes expanding hospital access to Tier-2 and Tier-3 cities, and growing chronic disease management demand. Hospitals that can sustain occupancy above 70% and hold Average Revenue Per Occupied Bed (ARPOB) steady are typically rewarded with operating efficiency gains flowing through to the bottom line. Against that backdrop, the BlueJet Healthcare Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, operating, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.

Click Here – Get Free Investment Predictions

BlueJet Healthcare Q1 Results FY27 Financial Highlights

All figures below are as reported by BlueJet Healthcare and sourced from the Q1 FY27 results announcement. Revenue figures are in Rs Crore (3 August 2026).

BlueJet Healthcare Q1 FY27 Performance Analysis

Revenue contracted this quarter, the most visible headwind in the numbers. BlueJet Healthcare reported Rs 293 Cr, down -17.40% from Rs 355 Cr in Q1 FY26. Investors will want to understand whether this is a cyclical correction, a volume/mix issue, or something more structural.

EBITDA fell -19.00% to Rs 98 Cr at 33.4% of revenue. Margin held broadly steady at 33.4% against 34.0% a year ago. The operating earnings decline is significant because it tells investors the revenue weakness is flowing through to profit rather than being absorbed by cost cuts, a more difficult dynamic to reverse quickly.

BlueJet Healthcare saw its net profit (PAT) contract this quarter. Rs 78 Cr compares with Rs 91 Cr a year earlier, a fall of -14.20%. Margin compression is the story here, and investors will want a clear path to recovery before re-engaging.

Check the Univest Screener for Live Data

BlueJet Healthcare Q1 FY27: Key Business Factors

1. Revenue: What Drove the Quarter

Revenue fell -17.40% to Rs 293 Cr from Rs 355 Cr in Q1 FY26. A revenue contraction in this sector can stem from destocking at the channel level, pricing concessions to maintain volume, or a loss of market share. BlueJet Healthcare will need to explain in the earnings call which combination was at play, and whether the drivers are temporary (destocking) or structural (share loss). The answer will define the stock’s re-rating narrative for FY27.

2. EBITDA and Margins: The Operating Health Check

EBITDA margin came in at 33.4%, broadly stable versus 34.0% in Q1 FY26 , a 0.6 percentage point movement either way. Margin stability in the healthcare sector is an acceptable outcome, particularly in a quarter where occupancy levels, regulatory approvals and cost of medical talent can push costs higher. That said, flat margins over multiple quarters would signal that the business is not generating the operating efficiency gains that investors typically expect at this stage of revenue growth.

3. PAT: What the Bottom Line Tells You

BlueJet Healthcare reported net profit of Rs 78 Cr for the quarter against Rs 91 Cr a year earlier. The net profit is the number that ultimately flows through to earnings per share (EPS) and determines the P/E multiple at which the stock trades. A -14.20% year on year improvement in this line is the most watched element of the quarterly results from a valuation standpoint. Analysts will now update their full-year FY27 earnings estimates based on this Q1 run rate and any guidance that management provides alongside the results.

BlueJet Healthcare Q1 FY27 Results vs Expectations

Analyst estimates for the BlueJet Healthcare Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 293 Cr and net profit of Rs 78 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on revenue and earnings simultaneously, the first trading session typically sees a positive price reaction as short sellers cover and institutional buyers step in. A miss on both is the reverse. A mixed print, beating on one line and missing on another, is harder to read and usually means the stock stays range-bound until the conference call provides clarity. Investors can track how BlueJet Healthcare is trading on the Univest Screener alongside analyst verdict updates after this result.

Dividend Update

Specific dividend information was not confirmed as part of this results snapshot. Most companies declare their dividend at the annual board meeting rather than the Q1 result. Investors tracking BlueJet Healthcare for its dividend yield should check the official NSE or BSE exchange filing, the company’s investor relations page, or the Univest Screener for the latest record date and payout details.

BlueJet Healthcare Outlook After the Q1 FY27 Results

For BlueJet Healthcare specifically, the Q1 FY27 trends point to decline in revenue and decline in the bottom line. Whether FY27 ends up as a year of acceleration, consolidation, or pressure depends largely on two variables: whether the decline in revenue sustains through Q2-Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter’s print. Management guidance, either in a formal earnings call or through an investor presentation, will be the single most important datapoint for updating FY27 forecasts.

The Q1 FY27 print gives investors a base to work from, but one quarter is rarely enough to conclude a trend. The key follow-up question for BlueJet Healthcare is whether the Q1 performance was driven by seasonal tailwinds or something more durable. Q2 FY27 results, due around October 2026, will be the first test of that. Investors should also watch for any corporate actions, debt announcements, or management changes in the interim.

Is BlueJet Healthcare a Good Buy After the Q1 FY27 Results?

The question investors most want answered after any quarterly result is whether it changes the investment thesis. For BlueJet Healthcare, the BlueJet Healthcare Q1 results FY27 show revenue of Rs 293 Cr, EBITDA of Rs 98 Cr, and net profit of Rs 78 Cr. Whether these numbers are ‘good’ depends on the price the stock is trading at, the FY27 full-year earnings estimate, and whether this Q1 run-rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor (Univest is SEBI RA INH000013776) before making any investment decision.

BlueJet Healthcare Share Price After the Q1 Results

Live price data for BlueJet Healthcare was not part of the results snapshot, but the stock typically reacts to Q1 results in the trading session following the announcement. Investors should check the live quote, the 52 week high and low, and technical support and resistance levels on the Univest Screener to contextualise the post-result price move before taking any action. A short-term price move immediately after results is often driven by event-driven traders rather than fundamental investors, and can reverse within the first few sessions.

Download the Univest iOS App or Univest Android App to track BlueJet Healthcare live share price and upcoming quarterly results.

Key Risks Investors Should Track

Before acting on the BlueJet Healthcare Q1 results FY27, investors should weigh these risks carefully.

1. Sector and Margin Risk

BlueJet Healthcare operates in the healthcare sector, which is exposed to occupancy levels, regulatory approvals and cost of medical talent. A reversal in the trends visible in the Q1 FY27 numbers, particularly on the margin front, could put the full-year FY27 earnings estimate at risk and weigh on the stock.

2. Single-Quarter Noise vs Trend

Quarterly results can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals. The Q1 FY27 print should be read alongside Q2 trends before drawing conclusions about the underlying trajectory of the business.

3. Macro and External Risk

Broader macro factors, RBI rate decisions, INR/USD movements, global commodity prices, and rural versus urban demand splits, can shift the business environment in the healthcare sector faster than company-level actions can compensate for.

Conclusion

The BlueJet Healthcare Q1 results FY27 show revenue of Rs 293 Cr (-17.40% year on year) and net profit of Rs 78 Cr (versus Rs 91 Cr in Q1 FY26). EBITDA came in at Rs 98 Cr with a 33.4% margin. A revenue decline and pressure on the bottom line were the two key themes of the quarter. Investors tracking BlueJet Healthcare should use this result as the Q1 FY27 baseline and watch Q2 FY27 results, due around October 2026, as the first real test of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.

Frequently Asked Questions on BlueJet Healthcare Q1 Results FY27

What were BlueJet Healthcare’s Q1 FY27 results?

Ans. BlueJet Healthcare reported revenue of Rs 293 Cr for Q1 FY27 (quarter ended 30 June 2026), down -17.40% year on year from Rs 355 Cr in Q1 FY26. PAT came in at Rs 78 Cr, compared with Rs 91 Cr a year ago, a change of -14.20%.

What is the PAT in BlueJet Healthcare Q1 results FY27?

Ans. BlueJet Healthcare reported net profit of Rs 78 Cr for Q1 FY27, versus Rs 91 Cr in Q1 FY26. The change was -14.20%.

What was BlueJet Healthcare’s revenue in Q1 FY27?

Ans. BlueJet Healthcare reported revenue of Rs 293 Cr for the June 2026 quarter, a change of -17.40% from Rs 355 Cr in Q1 FY26.

What was the EBITDA in BlueJet Healthcare Q1 FY27 results?

Ans. EBITDA for the quarter was Rs 98 Cr, down -19.00% from Rs 121 Cr in Q1 FY26. EBITDA margin was 33.4%.

When did BlueJet Healthcare announce Q1 FY27 results?

Ans. BlueJet Healthcare announced its Q1 FY27 results at 12:54 PM IST on 3 August 2026, for the quarter ended 30 June 2026. Investors should confirm the exact board meeting date and the results filing date from the official NSE or BSE announcement.

What is the outlook for BlueJet Healthcare after the Q1 FY27 results?

Ans. Following the Q1 FY27 results, analysts will update FY27 estimates for BlueJet Healthcare based on the quarterly run rate. Key things to watch: whether the decline in revenue continues into Q2 FY27, the trajectory of margins, and management guidance in the earnings call.

Is BlueJet Healthcare a good investment after Q1 FY27 results?

Ans. Investment decisions should be based on the stock’s current valuation relative to its earnings trajectory, not on a single quarterly result in isolation. The Q1 FY27 numbers (revenue Rs 293 Cr, net profit Rs 78 Cr) provide the Q1 baseline. Check the P/E and peer comparison on the Univest Screener and consult a SEBI-registered advisor before investing.